sangamo-041918-8024-rt2

Sangamo

4 June 2018Americas

ZFN: a rival to CRISPR

While CRISPR gene-editing and the battle over its patents continue to dominate headlines, a lesser known contender is making a name for itself, partly thanks to the drive of one company.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Counsel grapple with AI’s impact on training and critical thinking

LSPN: Trump's policy storm causing chaos and confusion

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Foley adds five-partner team from Perkins Coie and K&L Gates

US warns of rising counterfeit drug threat from India and China